Clinical trials: Multiple Dose
Cystic Fibrosis
Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis
This is a 3-part, single-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy volunteers (Part A) and multiple-ascending dose Phase 1a randomized, double-blind, placebo-controlled study in healthy…
- Trial name
- ABCI (NCT05802264)
- Testing
- ABCI
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Cystetic Medicines, Inc.
Major Depressive Disorder
Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers
The objectives of this study were to examine the cardiovascular sensitivity to oral tyramine after establishment of steady state with CX157 Modified Release (MR) Tablets, 125 mg administered twice per day (BID) in healthy…
- Trial name
- CX157-112 (NCT01633437)
- Testing
- CX157
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- CeNeRx BioPharma Inc.
Heart Failure
Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427
This first-time-in-human (FTIH) study will be conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of single doses of AZD3427 in healthy volunteers and multiple doses of…
- Trial name
- NCT04630067
- Testing
- AZD3427
- Where
- 10 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants
The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on how fast different formulations of midazolam gets into the blood stream and how long it takes the body to remove it when administered in…
- Trial name
- NCT06180967
- Testing
- Midazolam Syrup, Midazolam Solution, Pirtobrutinib
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Safety and Tolerability Study of ABT-126 in Elderly
The objectives of this study are to assess the safety, tolerability and pharmacokinetics of ABT-126 in elderly subjects.
- Trial name
- NCT00867399
- Testing
- ABT-126
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Abbott
Overweight or Obesity, Type 2 Diabetes
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and…
- Trial name
- T2DM (NCT06615700)
- Testing
- NA-931
- Where
- 2 sites in Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Asthma, Atopic Dermatitis
A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis
The purpose of this study is to evaluate the safety and tolerability of single ascending dose of CNTO 7160 administered intravenously (IV) in healthy participants and multiple dose administered IV in participants with asthma and…
- Conditions
- Asthma, Atopic Dermatitis, Healthy
- Trial name
- NCT02345928
- Testing
- Part 1: CNTO 7160, Part 2 (Asthma): CNTO 7160, Part 2 (Atopic Dermatitis): CNTO 7160
- Where
- 7 sites in Belgium, Germany
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Cystic Fibrosis
A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects
This study evaluated the safety and pharmacokinetics of multiple ascending doses of VX-440 in combination with tezacaftor/ivacaftor (TEZ/IVA) (triple combination [TC]) administered for 13 days to healthy male and female subjects
- Trial name
- NCT03486236
- Testing
- VX-440, TEZ, IVA
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Healthy Subjects
Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis
The purpose of this study is to establish if BMS-986165 is safe and effective at treating autoimmune diseases. BMS-986165 which has shown some promise in preclinical studies for inhibiting autoimmune conditions.
- Trial name
- NCT02534636
- Testing
- BMS-986165, Interferon alpha-2a recombinant, Famotidine
- Where
- Australia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers
This was a first-in-human study to determine the safety, tolerability, and pharmacokinetics of EI1071 after single and multiple doses in healthy volunteers.
- Trial name
- NCT04238364
- Testing
- EI-1071
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Elixiron Immunotherapeutics Inc.
Dry Eye
Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I)
The purpose of this two-part study is to evaluate safety, tolerability and pharmacokinetics of 0.5% and 2.5% cis-UCA eye drops in comparison to placebo in adult healthy volunteers.
- Trial name
- NCT01476332
- Testing
- cis-urocanic acid 0,5% eye drops, cis-urocanic acid 2.5% eye drops
- Where
- Finland
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Laurantis Pharma, Ltd.
Chronic Obstructive Pulmonary Disease
Multiple Dose Healthy Volunteer Safety Pharmacokinetics Study
Multiple dose safety and pharmacokinetics in healthy male subjects
- Trial name
- NCT00864786
- Testing
- PF03635659
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Adults
A Study（Phase I）of GS3-007a Dry Suspension in Healthy Chinese Adults
This study consists of two parts: the first part is a single-dose escalating（SAD） and food effect （FE）study, and the second part is a multiple-dose (14-day) escalating(MAD) study.
- Trial name
- NCT07473570
- Testing
- GS3-007a for Suspension
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Crohn's Disease
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease…
- Trial name
- NCT01258205
- Testing
- AMG 139
- Where
- 7 sites in United States, Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Contraception, Menopause
Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers
Estetrol (E4) is being developed in two indications supporting women health care: first E4 is combined with a progestin, [drospirenone (DRSP)] and is used as a new combined oral contraceptive (COC) for the prevention of pregnancy…
- Trial name
- NCT03075956
- Testing
- 5 mg E4 single-dose, 15 mg E4 single-dose, 45 mg E4 single-dose
- Where
- Bulgaria
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Estetra
Smoking Cessation
A First-in-Human Study of SBP-9330 in Healthy Subjects
This is a single center, first-in-human, randomized, double-blind, placebo-controlled, Single-Ascending Dose (SAD) / Multiple-Ascending Dose (MAD) study incorporating a food-effect cohort.
- Trial name
- NCT04948827
- Testing
- SBP-9330
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Camino Pharma, LLC
Psoriasis Vulgaris
LEO 32731 - A Phase I Study in Healthy Subjects
LEO 32731 ("Study Drug") is an investigational drug which is being developed by LEO Pharma A/S ("the Sponsor") for treatment of psoriasis.
- Trial name
- NCT02514694
- Testing
- LEO32731
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Rheumatoid Arthritis (RA), Inflammatory Bowel Disease - IBD1
Phase I Clinical Study of ZL-82 Tablets
ZL-82 is an oral janus kinase (JAK) inhibitor. In vitro biological mass spectrometry identification test proves that ZL-82 can selectively and irreversibly inhibit JAK3.
- Trial name
- NCT06055023
- Testing
- ZL-82 12.5mg, ZL-82 25mg, ZL-82 50mg
- Where
- China
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
This trial is conducted in Asia. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), pharmacodynamics (the effect of the investigated drug on the body), and the safety and…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02146079
- Testing
- semaglutide
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Participants
A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2072 Tablets
This is a first-in-human study to evaluate the safety, tolerability, PK, and PD characteristics of SYH2072 Tablets after single and multiple oral doses in healthy participants.
- Trial name
- NCT07647783
- Testing
- SYH2072 Tablets
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- InnovStone Therapeutics Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.